View allAll Photos Tagged ClinicalTrials
Poster 6/39
Depression relapse prophylaxis with mindfulness-based cognitive therapy: replication and extension in the swiss healthcare system
Heba Degheidy, M.D., Ph.D., a visiting research associate at FDA, stores stem cell samples for analysis in an FDA laboratory on the National Institutes of Health campus in Bethesda, Md.
To learn more about stem cell research, read this FDA Consumer Update:
Adult Stem Cell Research Shows Promise
This photo is free of all copyright restrictions and available for use and redistribution without permission. Credit to the U.S. Food and Drug Administration is appreciated but not required.
Privacy and use information: www.flickr.com/people/fdaphotos/
FDA photo by Michael J. Ermarth
Aided by a high-powered brain scanner and a 3D printer, NIH researchers peered inside the brains of hundreds of multiple sclerosis patients and found that dark rimmed spots representing ongoing, “smoldering” inflammation, called chronic active lesions, may be a hallmark of more aggressive and disabling forms of the disease.
“We found that it is possible to use brain scans to detect which patients are highly susceptible to the more aggressive forms of multiple sclerosis. The more chronic active lesions a patient has the greater the chances they will experience this type of MS,” said Daniel S. Reich, M.D., Ph.D., senior investigator at the NIH’s National Institute of Neurological Disorders and Stroke and the senior author of the paper published in JAMA Neurology. “We hope these results will help test the effectiveness of new therapies for this form of MS and reduce the suffering patients experience.”
Learn more: www.nih.gov/news-events/news-releases/smoldering-spots-br...
Credit: National Institute of Neurological Disorders and Stroke/NIH
An infographic designed to clarify the different kinds of clinical studies researchers use, to explain why researchers might use them, and to touch briefly on each type’s strengths and weaknesses.
More information: www.nih.gov/institutes-nih/nih-office-director/office-com...
Credit: National Institutes of Health
Findings from a phase 2 clinical trial show that the drug selumetinib improves outcomes for children with the genetic disorder neurofibromatosis type 1 (NF1). In the trial, selumetinib shrank the inoperable tumors that develop with NF1 called plexiform neurofibromas, and children experienced reduced pain, improved function, and better overall quality of life after receiving the treatment.
Read more: www.nih.gov/news-events/news-releases/nih-trial-selumetin...
In this image: Dr. Brigitte Widemann with Travis Carpenter, who received selumetinib for NF1 at NIH.
Credit: National Cancer Institute, NIH
I was delighted to have the chance to envizualize (create large scale visual notes) for the Disruptive Innovations to Advance Clinical Trials Conference in Boston. From the conference website: "This conference is designed for drug development innovative thinkers who are determined to re-invent clinical trials. It is an outcomes-focused program that not only delves deeply into the key strategic factors impeding clinical trial productivity, but also endeavors to connect change makers who can share current solutions, propose new solutions and commit to testing them and share the results."
In this image: Mr. Curtis Minor, 58 year old AA Male who is taking part in the SPRINT study at Downtown Health Plaza with Miriam Baird, RN.
A major NIH-funded clinical trial has discovered nuanced evidence linking brain and vascular health.
Learn more: www.nih.gov/news-events/news-releases/does-intensive-bloo...
Credit: Wake Forest School of Medicine
NIH support from: NIA, NHLBI, NIDDK and NINDS
For women in resource-poor settings, taking a certain daily nutritional supplement before conception or in early pregnancy may provide enough of a boost to improve growth of the fetus, according to an NIH-funded study. The inexpensive supplement consists of dried skimmed milk, soybean and peanut extract blended into a peanut butter-like consistency. Weighing less than an ounce, the supplement is fortified with essential vitamins and minerals and provides protein and fatty acids often lacking in the women’s diets. In this image, a participant in the trial prepares the supplement.
Read more: www.nih.gov/news-events/news-releases/inexpensive-supplem...
Credit: Nancy Krebs University of Colorado Anschutz Medical Campus, Aurora, CO
NIH support from: Eunice Kennedy Shriver National Institute of Child Health and Human Development
Jessica Lo Surdo, M.S. (foreground), an FDA staff scientist, studies chain reactions in stem cells in an FDA laboratory on the National Institutes of Health campus in Bethesda, Md. Ross Marklein, Ph.D., a post-doctoral research fellow (background), records findings.
To learn more about stem cell research, read this FDA Consumer Update:
Adult Stem Cell Research Shows Promise
This photo is free of all copyright restrictions and available for use and redistribution without permission. Credit to the U.S. Food and Drug Administration is appreciated but not required.
Privacy and use information: www.flickr.com/people/fdaphotos/
FDA photo by Michael J. Ermarth
A participant receives an injection in an NIH trial examining a vaccine intended to provide broad protection against a range of mosquito-borne diseases.
More information: www.nih.gov/news-events/news-releases/nih-begins-study-va...
Credit: National Institute on Allergy and Infectious Diseases, National Institutes of Health
In a new study from the National Cancer Institute (NCI), part of the National Institutes of Health, researchers found a higher than expected prevalence of cancer at baseline screening in individuals with Li-Fraumeni syndrome (LFS), a rare inherited disorder that leads to a higher risk of developing certain cancers. The research demonstrates the feasibility of a new, comprehensive cancer screening protocol for this high-risk population.
This image is part of a representative image of a whole body MRI of an LFS patient. Arrow denotes lesion found to be lung adenocarcinoma.
More information: www.nih.gov/news-events/news-releases/nci-study-shows-fea...
Credit: National Cancer Institute, NIH
A clinical trial has begun to examine the safety and use of two HIV prevention tools—oral pre-exposure prophylaxis (PrEP) and a vaginal ring—in adolescent girls and young women in southern Africa. Funded by the National Institutes of Health, the trial is designed to contribute to the delivery of safe, effective and desirable choices of HIV prevention methods for adolescent girls and young women, who are disproportionately affected by the HIV epidemic.
Learn more: www.nih.gov/news-events/news-releases/study-prep-vaginal-...
Credit: National Institute of Allergy and Infectious Diseases/NIH
Topical treatment with live Roseomonas mucosa — a bacterium naturally present on the skin — was safe for adults and children with atopic dermatitis (eczema) and was associated with reduced disease severity, according to initial findings from an ongoing early-phase clinical trial at the National Institutes of Health.
In this image, a scientist demonstrates application of the experimental therapy to the inner elbow. For demonstration purposes, the bacteria solution has been replaced with purple dye.
More info: www.nih.gov/news-events/news-releases/bacteria-therapy-ec...
Credit: National Institute of Allergy and Infectious Diseases, NIH
Using a novel patient-specific stem cell-based therapy, researchers at the National Eye Institute (NEI) prevented blindness in animal models of geographic atrophy, the advanced "dry" form of age-related macular degeneration (AMD), which is a leading cause of vision loss among people age 65 and older. The protocols established by the animal study, published January 16 in Science Translational Medicine (STM), set the stage for a first-in-human clinical trial testing the therapy in people with geographic atrophy, for which there is currently no treatment.
As pictured in this illustration, researchers will take a patient's blood cells and convert them in a lab to induced Pluripotent Stem cells (iPS cells) which are capable of becoming any type of cell in the body. iPS cells would then be programmed to become retinal pigment epithelial (RPE) cells, the type of cell that dies early in the geographic atrophy form of AMD.
Read more: www.nih.gov/news-events/news-releases/nih-researchers-res...
Credit: National Eye Institute, NIH
Researchers from the National Institutes of Health Kevin D. Hall, Ph.D., center, and Stephanie Chung, M.B.B.S., right, talk with a study participant at the NIH Clinical Center.
People eating ultra-processed foods ate more calories and gained more weight than when they ate a minimally processed diet, according to results from a National Institutes of Health study. The difference occurred even though meals provided to the volunteers in both the ultra-processed and minimally processed diets had the same number of calories and macronutrients.
Read more: www.nih.gov/news-events/news-releases/nih-study-finds-hea...
Credit: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)/NIH
In a nationwide study, researchers used magnetic resonance imaging (MRI) to scan the brains of hundreds of participants in the National Institutes of Health’s Systolic Blood Pressure Intervention Trial (SPRINT) and found that intensively controlling a person’s blood pressure was more effective at slowing the accumulation of white matter lesions than standard treatment of high blood pressure. The results complement a previous study published by the same research group which showed that intensive treatment significantly lowered the chances that participants developed mild cognitive impairment.
Read more: www.nih.gov/news-events/news-releases/intensive-blood-pre...
Credit: SPRINT MIND Investigators, NIH
An adult volunteer in Mali receives the experimental malaria vaccine known as PfSPZ Vaccine.
The vaccine was well-tolerated and protected a significant proportion of healthy adults against infection with Plasmodium falciparum malaria — the deadliest form of the disease — for the duration of the malaria season, according to new findings published in the February 15th issue of the journal Lancet Infectious Diseases.
More information: www.nih.gov/news-events/news-releases/investigational-pfs...
Credit: National Institute of Allergy and Infectious Diseases, National Institutes of Health
In April of 2016, experts at the NIH began a first-in-human trial to attempt to treat Progressive Multifocal Leukoencephalopathy (PML), a rare, often fatal brain disease, in patients with immunosuppression, such as patients who have recently undergone organ transplant, stem cell transplant or cancer treatment.
The study involves extracting certain blood cells from a healthy relative of a patient with PML, manipulating them in the Clinical Center Cell Processing Section lab and then injecting them into the patient.
In the photo above, Sue Ellen Frodigh, a lead technologist in the Clinical Center's Cell Processing Section, checks on the cells.
Credit: Clinical Center, National Institutes of Health
I was delighted to have the chance to envizualize (create large scale visual notes) for the Disruptive Innovations to Advance Clinical Trials Conference in Boston. From the conference website: "This conference is designed for drug development innovative thinkers who are determined to re-invent clinical trials. It is an outcomes-focused program that not only delves deeply into the key strategic factors impeding clinical trial productivity, but also endeavors to connect change makers who can share current solutions, propose new solutions and commit to testing them and share the results."
A scanning electron micrograph image shows a polarized RPE monolayer on a biodegradable scaffold. The image is colored to highlight the scaffold in blue, three RPE cells (brown), and the apical process of cells in RPE monolayer are light green.
Read more about a possible clinical trial for a stem cell based therapy to treat age-related macular degeneration (AMD):
www.nih.gov/news-events/news-releases/nih-researchers-res...
Credit: National Eye Institute, NIH
Prostate cancer patients of low socioeconomic status have delayed diagnosis, poor tumor assessment, and less aggressive treatments with important disease overmortality as a consequence.
I was delighted to have the chance to envizualize (create large scale visual notes) for the Disruptive Innovations to Advance Clinical Trials Conference in Boston. From the conference website: "This conference is designed for drug development innovative thinkers who are determined to re-invent clinical trials. It is an outcomes-focused program that not only delves deeply into the key strategic factors impeding clinical trial productivity, but also endeavors to connect change makers who can share current solutions, propose new solutions and commit to testing them and share the results."
Jessica Lo Surdo, M.S., an FDA staff scientist, studies chain reactions in stem cells in an FDA laboratory on the National Institutes of Health campus in Bethesda, Md.
To learn more about stem cell research, read this FDA Consumer Update:
Adult Stem Cell Research Shows Promise
This photo is free of all copyright restrictions and available for use and redistribution without permission. Credit to the U.S. Food and Drug Administration is appreciated but not required.
Privacy and use information: www.flickr.com/people/fdaphotos/
FDA photo by Michael J. Ermarth
I was delighted to have the chance to envizualize (create large scale visual notes) for the Disruptive Innovations to Advance Clinical Trials Conference in Boston. From the conference website: "This conference is designed for drug development innovative thinkers who are determined to re-invent clinical trials. It is an outcomes-focused program that not only delves deeply into the key strategic factors impeding clinical trial productivity, but also endeavors to connect change makers who can share current solutions, propose new solutions and commit to testing them and share the results."
Ross Marklein, Ph.D., a post-doctoral research fellow at FDA, examines images of stem cells in an FDA laboratory on the National Institutes of Health campus in Bethesda, Md.
To learn more about stem cell research, read this FDA Consumer Update:
Adult Stem Cell Research Shows Promise
This photo is free of all copyright restrictions and available for use and redistribution without permission. Credit to the U.S. Food and Drug Administration is appreciated but not required.
Privacy and use information: www.flickr.com/people/fdaphotos/
FDA photo by Michael J. Ermarth
Ross Marklein, Ph.D., a post-doctoral research fellow at FDA, examines images of stem cells in an FDA laboratory on the National Institutes of Health campus in Bethesda, Md.
To learn more about stem cell research, read this FDA Consumer Update:
Adult Stem Cell Research Shows Promise
This photo is free of all copyright restrictions and available for use and redistribution without permission. Credit to the U.S. Food and Drug Administration is appreciated but not required.
Privacy and use information: www.flickr.com/people/fdaphotos/
FDA photo by Michael J. Ermarth
I was delighted to have the chance to envizualize (create large scale visual notes) for the Disruptive Innovations to Advance Clinical Trials Conference in Boston. From the conference website: "This conference is designed for drug development innovative thinkers who are determined to re-invent clinical trials. It is an outcomes-focused program that not only delves deeply into the key strategic factors impeding clinical trial productivity, but also endeavors to connect change makers who can share current solutions, propose new solutions and commit to testing them and share the results."
Steven Bauer, Ph.D., chief of the Cellular and Tissue Therapy Branch in FDA’s Office of Cellular Tissue and Gene Therapies (standing), visits his team of scientists in an FDA laboratory on the National Institutes of Health campus in Bethesda, Md.
To learn more about stem cell research, read this FDA Consumer Update:
Adult Stem Cell Research Shows Promise
This photo is free of all copyright restrictions and available for use and redistribution without permission. Credit to the U.S. Food and Drug Administration is appreciated but not required.
Privacy and use information: www.flickr.com/people/fdaphotos/
FDA photo by Michael J. Ermarth
Jessica Lo Surdo, M.S. (foreground), an FDA staff scientist, studies chain reactions in stem cells in an FDA laboratory on the National Institutes of Health campus in Bethesda, Md. Ross Marklein, Ph.D., a post-doctoral research fellow (background), records findings.
To learn more about stem cell research, read this FDA Consumer Update:
Adult Stem Cell Research Shows Promise
This photo is free of all copyright restrictions and available for use and redistribution without permission. Credit to the U.S. Food and Drug Administration is appreciated but not required.
Privacy and use information: www.flickr.com/people/fdaphotos/
FDA photo by Michael J. Ermarth
I was delighted to have the chance to envizualize (create large scale visual notes) for the Disruptive Innovations to Advance Clinical Trials Conference in Boston. From the conference website: "This conference is designed for drug development innovative thinkers who are determined to re-invent clinical trials. It is an outcomes-focused program that not only delves deeply into the key strategic factors impeding clinical trial productivity, but also endeavors to connect change makers who can share current solutions, propose new solutions and commit to testing them and share the results."
Max Saunders-Singer as Michael and Hanna Kass as Saira
Y Touring Theatre Company and the Learning Participation Team present 'Starfish' at the Royal Albert Hall's Elgar Room.
'Starfish' was written by Judith Johnson, directed by Nigel Townsend and designed by Jaimie Todd.
© Shelia Burnett
Susan Elkin The Stage
I’m at a girls’ school in a delightfully traditional building overlooking Parsons Green. It would have been a lot easier to get here had there been any Wimbledon trains on the District Line when I needed them, but never mind — I’m at Lady Margaret School now.
Y Touring — a company whose interesting activities and ideas I have followed for nearly twenty years — is doing the last performance of its spring tour to schools this afternoon: Starfish by Judith Johnson.
The play is fascinating, sensitively done and deeply moving, although the reactions of the mature, thoughtful 15 year old girls - the whole of Year 10 - are almost as interesting.
We are in a small Northern town. Saira, a young doctor (Hanna Kass - very good), comes back to practise in her father’s old surgery following his death. At the centre of the story is bright, kind, 20-something Michael (Max Saunders Singer, pictured above with Hanna Kass) a young teacher who develops variant CJD. The play charts the diagnosis, the disease, and the heartbreak that follows for those around him. Saira, deeply attached to Michael, is nevertheless a constant advocate for the need for fair clinical trials, the danger of untried treatments and the requirement of individuals to play their part in the process. But Michael’s dad, Adrian (Andrew Hobday) wants to prolong his son’s life at any cost.
Meanwhile, encouraged by Michael, Shannon (Susannah Freeman, pictured right) one of his students, begins to fight her Social Phobia through an online existence in Second Life which helps her to grow more confident. She continues, however, to struggle in the real world. Could a properly managed trial in a virtual world equip her with the resilience she needs to face her fears?
The Lady Margaret girls are led through a brief introductory session and there’s a well managed discussion at the end during which everyone votes on ethical questions using individual hand held devices. The results are displayed instantly on a screen at the end of the room. ‘A bit like “Who wants to be a millionaire?” ’ the facilitator jokes to lighten the atmosphere, well aware that several girls are in tears at the end of the play and one has left the room followed by a friend to comfort her.
Yes, Starfish is a very powerful piece and anyone watching it is bound to travel his or her own journey. I too had to brush away tears as I thought about my father who agreed to several untried experiments - which may have hastened his decline into the renal failure which eventually killed him - when he was suffering from Guilluame Barre Syndrome, a hideous, incurable neurological condition. But my Dad, like Adrian in the play, regarded it as a ‘nothing to lose’ situation and was willing to try absolutely anything. A valid point of view, perhaps.
The play has attracted a number of accolades. John Flint, Post-16 Learning Manager, Harry Carlton School, Loughbrough found Starfish ‘A very positive experience and useful in the sense that it seeks to break down the necessary pragmatism of the false demarcations between discrete subject areas such as science and morality and hence philosophy and ethics - an interesting step towards holistic education.’
John Billington is Head of Personal, Social and Health Education (PSHE) at Carter Community School in Poole. ‘The way in which drama can introduce complicated issues and multi-layered discussion is a constant source of delight,’ he said of Starfish.
Y Touring, the first company to work in the arena of health, sex education and science ethics, is Central YMCA’s award-winning Touring Theatre Company, established in 1989.
“Through creating high quality theatre and drama we aim to highlight important, often difficult, current issues and empower its audiences of young people and adults to generate change in themselves, others and society,” artistic director Nigel Townsend tells me.
But - and this is a big ‘but’ - the company does not (definitely not) do all this at the expense of producing powerful theatre. Like the rest of the audience I was totally absorbed by the Starfish narrative and both impressed and shaken by Saunders Singer’s depiction of a severely disabled, wheelchair-bound, palsied young man who had been playing tennis only a few weeks earlier.
Accompanying the play is a virtual online world, Steamfish, which allows students to experience a clinical trial based on James Lind’s initial clinical trial for scurvy. The virtual world combines education and entertainment as students take on a quest to find a way off an island after a shipwreck, while also taking part in a clinical trial.
Steamfish has been developed by Y Touring in partnership with Rezzable Productions Ltd. It is a secure, private, online environment where students will ‘meet’ only other students and Y Touring and Rezzable staff.
Download and listen to the radio adaptation of Starfish at www.theatreofdebate.com
Heba Degheidy, M.D., Ph.D., a visiting research associate at FDA, works with stem cell samples in an FDA laboratory on the National Institutes of Health campus in Bethesda, Md.
To learn more about stem cell research, read this FDA Consumer Update:
Adult Stem Cell Research Shows Promise
This photo is free of all copyright restrictions and available for use and redistribution without permission. Credit to the U.S. Food and Drug Administration is appreciated but not required.
Privacy and use information: www.flickr.com/people/fdaphotos/
FDA photo by Michael J. Ermarth
Heba Degheidy, M.D., Ph.D., a visiting research associate at FDA, works with stem cell samples in an FDA laboratory on the National Institutes of Health campus in Bethesda, Md.
To learn more about stem cell research, read this FDA Consumer Update:
Adult Stem Cell Research Shows Promise
This photo is free of all copyright restrictions and available for use and redistribution without permission. Credit to the U.S. Food and Drug Administration is appreciated but not required.
Privacy and use information: www.flickr.com/people/fdaphotos/
FDA photo by Michael J. Ermarth
Steven Bauer, Ph.D., chief of the Cellular and Tissue Therapy Branch in FDA’s Office of Cellular Tissue and Gene Therapies (standing), visits his team of scientists in an FDA laboratory on the National Institutes of Health campus in Bethesda, Md.
To learn more about stem cell research, read this FDA Consumer Update:
Adult Stem Cell Research Shows Promise
This photo is free of all copyright restrictions and available for use and redistribution without permission. Credit to the U.S. Food and Drug Administration is appreciated but not required.
Privacy and use information: www.flickr.com/people/fdaphotos/
FDA photo by Michael J. Ermarth
Do you have a duty to participate in research? This was the first topic of NWABR's Community Conversations, a series of bioethics salons bringing together the research community and the general public.
Heba Degheidy, M.D., Ph.D., a visiting research associate at FDA, stores stem cell samples for analysis in an FDA laboratory on the National Institutes of Health campus in Bethesda, Md.
To learn more about stem cell research, read this FDA Consumer Update:
Adult Stem Cell Research Shows Promise
This photo is free of all copyright restrictions and available for use and redistribution without permission. Credit to the U.S. Food and Drug Administration is appreciated but not required.
Privacy and use information: www.flickr.com/people/fdaphotos/
FDA photo by Michael J. Ermarth
Ross Marklein, Ph.D., a post-doctoral research fellow at FDA, examines images of stem cells in an FDA laboratory on the National Institutes of Health campus in Bethesda, Md.
To learn more about stem cell research, read this FDA Consumer Update:
Adult Stem Cell Research Shows Promise
This photo is free of all copyright restrictions and available for use and redistribution without permission. Credit to the U.S. Food and Drug Administration is appreciated but not required.
Privacy and use information: www.flickr.com/people/fdaphotos/
FDA photo by Michael J. Ermarth
Spirometry training with hand-held spirometer Spiropalm at University of Athens (Greece), Dept. of Hygiene, Epidemiology and Medical Statistics (en.uoa.gr/). Source: Serinth: www.serinth.gr/
this team is making drug capsules in small volume for a clinical trial, for
an unnamed client pharma company. They work for Pharmatek in San Diego.
“I do feel like I make a difference here in clinical research with the Heart and Vascular Institute,” said coordinator Katie Loffredo. “That’s something I feel real good about.”
CAPT Carmen T. Maher, MA, BSN, RN, RAC, is Acting Assistant Commissioner for Counterterrorism Policy at FDA. See CAPT Maher's leadership page on FDA's website.
This photo is free of all copyright restrictions and available for use and redistribution without permission. Credit to the U.S. Food and Drug Administration is appreciated but not required. For more privacy and use information visit: www.flickr.com/people/fdaphotos/
FDA photo by Michael J. Ermarth
The Coghlan Group, located in the Bastrop Business & Industrial Park, has a significant share of the market and President Terry Coghlan credits the operation’s location as a key advantage.
“There are probably about a dozen companies worldwide that do what we do, but most are in locations that can’t compete with what we have in terms of quality of life and local support for our business,” Coghlan said.
Coghlan started his company at a home office in Bastrop in 1996. He had been commuting to a related job in Austin when he set up his own shop. A year later he moved into a 235 sq. ft. office nearby. And by Christmas week, 2000, he moved his by-then five employees into the Bastrop industrial park.
Now he has 20 employees in a 20,000 sq. ft. building in the park. And as early as first quarter 2014, he is considering constructing a new 40,000 sq. ft. structure to bring on another 10-15 staff members, with the goal of capturing a larger share of the international market.
Pictures are courtesy of Precious Moments Photography in Bastrop Texas.